Welcome to our dedicated page for Vicarious Surgical news (Ticker: RBOT), a resource for investors and traders seeking the latest updates and insights on Vicarious Surgical stock.
Vicarious Surgical Inc (RBOT) combines advanced robotics with virtual reality to transform minimally invasive surgery. This news hub provides investors and healthcare professionals with essential updates about the company's technological advancements and market position.
Access real-time information about surgical robotics innovations, regulatory milestones, and strategic partnerships. Our curated collection includes earnings reports, product development announcements, and clinical trial updates directly impacting the future of abdominal surgery techniques.
Key focus areas include 3D visualization systems, single-port surgical interfaces, and integration with existing hospital workflows. Stay informed about developments in robotic-assisted procedures that enhance surgical precision while reducing patient recovery times.
Bookmark this page for verified updates about RBOT's progress in medical robotics. Regularly updated content ensures you maintain current awareness of technological breakthroughs and industry partnerships shaping modern surgical practices.
Vicarious Surgical (NYSE: RBOT) has appointed Sarah Romano as Chief Financial Officer, effective April 1, 2025. Romano brings decades of financial leadership experience in capital markets, particularly in the healthcare sector. She previously served as CFO of Entero Therapeutics, where she managed financial strategy and executed product in-licensing partnerships.
At her former position as CFO of Kiora Pharmaceuticals, Romano secured over $50 million in funding and led M&A activities. Her expertise includes financial strategy, operations, compliance, budget reviews, forecasting, internal controls oversight, and SEC reporting. Romano holds a Master of Accountancy from Boston College and a B.A. in Accounting from the College of the Holy Cross.
Vicarious Surgical (NYSE: RBOT) has scheduled its Fourth Quarter and Fiscal Year 2024 financial results announcement for March 17, 2025, after market close. The robotics technology company, focused on advancing robotic surgery, will host a conference call at 4:30 p.m. Eastern Time to discuss the results.
Investors can participate in the conference call by dialing +1 833-470-1428 (domestic) or +1 404-975-4839 (international) with access code 373279. A webcast will be available live and archived at the company's investor relations website.
Vicarious Surgical (NYSE: RBOT) announced that Chief Operating Officer John Mazzola will retire effective April 1, 2025, after nearly 40 years in healthcare manufacturing, supply chain, and quality control. Mazzola's responsibilities will transition to Company President Randy Clark.
According to CEO Adam Sachs, Mazzola has been key in developing manufacturing processes, enhancing product quality control, and strengthening supply chain resilience. The company states it is well-positioned for its next phase, including upcoming first clinical use cases and pivotal trial.
Vicarious Surgical (NYSE: RBOT) announced that Chief Financial Officer William Kelly will be departing the company on January 2, 2025. Kelly, who has served as CFO since January 2021, is leaving to pursue other career opportunities after nearly four years with the company.
Kelly will assist in ensuring a smooth transition of responsibilities before his departure. The company has initiated a CFO succession process and will provide updates accordingly. CEO Adam Sachs expressed gratitude for Kelly's significant contributions during his tenure.
Vicarious Surgical announced its Q3 2024 financial results. Operating expenses decreased by 17% to $17.8M from $21.4M in Q3 2023. R&D expenses dropped to $10.8M from $13.0M, general and administrative expenses fell to $5.7M from $6.9M, and sales and marketing expenses decreased to $1.2M from $1.4M. The adjusted net loss was $17.0M, or $2.87 per share, compared to $20.4M, or $3.95 per share, in the same period last year. GAAP net loss was $17.1M, or $2.90 per share, versus $15.7M, or $3.04 per share, last year. The company had $60.9M in cash and investments as of September 30, 2024, with a Q3 cash burn rate of $12.4M. Full-year 2024 cash burn is expected to be approximately $50M. CEO Adam Sachs highlighted the upcoming milestone for the Version 1.0 System integration and the goal to complete the first clinical patient within a year.
Vicarious Surgical (NYSE: RBOT) has announced it will release its third quarter 2024 financial results on November 12, 2024, after market close. The company will host a conference call at 4:30 p.m. Eastern Time to discuss the results. Investors can join via phone by dialing +1 833-470-1428 (domestic) or +1 404-975-4839 (international) using access code 246564. A webcast will be available on the company's investor relations website.
Vicarious Surgical Inc. (NYSE: RBOT), a pioneering robotics technology company focused on revolutionizing robotic surgery, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York. The company's management team is set to engage in a fireside chat on Friday, September 6, 2024, at 11:30 a.m. ET.
This presentation at a major healthcare conference highlights Vicarious Surgical's commitment to showcasing its innovative approach to improving surgical procedures through advanced robotics. The company's participation provides an opportunity for investors and industry professionals to gain insights into Vicarious Surgical's technology and future plans in the rapidly evolving field of robotic-assisted surgery.
Vicarious Surgical Inc. (NYSE: RBOT), a next-generation robotics technology company, reported its Q2 2024 financial results. The company is on track to achieve its V1.0 integration milestone this fall and aims for its first clinical patient around this time next year. Key highlights include:
- Partnership agreement with LSU Health New Orleans, the fifth U.S. hospital system to partner with Vicarious Surgical
- Operating expenses decreased by 17% to $17.7 million
- Adjusted net loss of $16.8 million ($2.86 per share)
- GAAP net loss of $15.2 million ($2.59 per share)
- Cash and investments of $73.2 million as of June 30, 2024
- Q2 2024 cash burn rate of $10.9 million
- Full year 2024 cash burn guidance reiterated at approximately $50 million
Vicarious Surgical (NYSE: RBOT) has signed a strategic development agreement with LSU Health New Orleans, Louisiana's flagship academic health sciences center. This partnership will provide Vicarious Surgical access to LSU Health's network of experienced robotic surgeons and supporting staff. The collaboration aims to validate training protocols and identify drivers of surgeon adoption for Vicarious Surgical's V1.0 system.
LSU Health New Orleans, which partners with University Medical Center (UMC), treats over 200,000 patients annually and is responsible for more than 1 million patient visits across its broader system. The partnership will allow Vicarious Surgical to conduct formative studies on the clinical and economic value of their system, particularly in regional care settings with an academic focus.
Vicarious Surgical Inc. (NYSE: RBOT), a next-generation robotics technology company focused on improving surgical robotics, has announced its plans to report second quarter 2024 financial results on August 12, 2024, after the market closes. The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results. Investors can participate in the call by dialing +1 833-470-1428 (domestic) or +1 404-975-4839 (international) using the access code 997268. Additionally, a live and archived webcast of the event will be available on the company's investor relations website.
FAQ
What is the current stock price of Vicarious Surgical (RBOT)?
What is the market cap of Vicarious Surgical (RBOT)?
